Abstract

Carvedilol (Eucardic - Boehringer Mannheim), a mixed α₁- and β-adrenoceptor blocker, has recently been licensed for the treatment of patients with all grades of hypertension. The manufacturer claims that its dual mode of action "extends the scope of β-blocker therapy" and "results in fewer of the unwanted effects typical with standard β-blockers". We examine the claims for carvedilol and consider its place in the management of hypertension.